Research suggest removal of fallopian tubes may lower risk of ovarian cancer - Examiner.com
Research suggest removal of fallopian tubes may lower risk of ovarian cancer Examiner.com This new recommendation is being made because of recent research has shown the fallopian tubes to be the source of some of the deadliest ovarian cancers. Removal of the fallopian tubes could reduce the risk of developing these forms of ovarian cancer.
Relay for Life to honor cancer survivors and patients, remember victims - New Jersey Herald
Relay for Life to honor cancer survivors and patients, remember victims New Jersey Herald Two weeks later, the tumor was removed along with one of her ovaries, appendix and a fallopian tube, she said. Today, Fattorusso walks a victory lap, shoulder-to-shoulder, with all the other survivors. The mother of four also walks for her grandmother, ...
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 - Sacramento Bee
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 Sacramento Bee A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162).
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 - PR Newswire (press release)
Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 PR Newswire (press release) ... Phase III trials in metastatic colorectal cancer, metastatic gastric adenocarcinoma and hepatocellular cancer, as well as results of a Phase II study in persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Add-on bevacizumab slows progression of recurrent ovarian cancer - Curetoday.com (press release)
Add-on bevacizumab slows progression of recurrent ovarian cancer Curetoday.com (press release) NEW YORK (Reuters Health) - Women with recurrent platinum-sensitive ovarian, peritoneal and fallopian tube cancers have had significantly longer progression-free survival (PFS) when bevacizumab was added to chemotherapy in an ongoing multicenter trial.
Risky Surgical Business - The Jewish Week
Risky Surgical Business The Jewish Week Her decision to remove her ovaries and fallopian tubes was painstaking; as a mother of young children, she didn't relish the thought of slipping into early menopause, never mind the physical stress of surgery or disruption of her family life.
A guide to endometrial cancer Fox News The other common surgeries are bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries) and radical hysterectomy (removal of the uterus, cervix and a portion of the vagina). After surgery, radiation or hormone therapy are ...
Bevacizumab Benefits Patients With Recurrent Ovarian Cancer - Medscape
Bevacizumab Benefits Patients With Recurrent Ovarian Cancer Medscape "This regimen should be considered a new option for recurrent platinum-sensitive ovarian cancer," she said. The cohort involved 484 patients with platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer who were randomized to ...
How to recognize ovarian cancer, known as the 'silent killer' - Fox News
How to recognize ovarian cancer, known as the 'silent killer' Fox News The goal of surgery is to remove the cancer from the ovaries and surrounding infected areas. This could necessitate removal of the ovaries, fallopian tubes, uterus, omentum and lymph nodes, depending on how far the cancer has spread.
What our clients and candidates are saying about us: I enjoyed visiting your site very much. You and your staff at SHS are doing an impressive job with this site. Your pride in what you do is very evident. - David
The #1 Resource for professionals in the Pharmaceutical Advertising, Medical Communications, Healthcare Public Relations, Pharmaceutical Industry, and Biotechnology fields since 1988.